The PCSK9 Forum Editorial Board discusses the impact of FOURIER on patient management:

• How can FOURIER be used to improve clinical practice?
• How can we ensure the best value from PCSK9 inhibitor therapy?

Prof Ulf Landmesser: How can we ensure the best value from PCSK9 inhibitor therapy?		Prof Steve Nicholls: How can FOURIER improve our clinical practice?		Prof Philip Barter: How do we translate the FOURIER data to clinical practice?		Prof Evan Stein: What are the key messages from FOURIER?		Prof Ulf Landmesser: How will FOURIER impact our practice?		Prof Steve Nicholls: Is there a link between the benefits of evolocumab in GLAGOV and FOURIER?